Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9833429 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8372828 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8536163 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8716271 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US9820959 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8735375 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US9861603 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8377919 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US9833428 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8372827 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8278292 | LEO LABS | Therapeutic compositions |
Jul, 2027
(3 years from now) | |
US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(9 years from now) |
Picato is owned by Leo Labs.
Picato contains Ingenol Mebutate.
Picato has a total of 12 drug patents out of which 0 drug patents have expired.
Picato was authorised for market use on 23 January, 2012.
Picato is available in gel;topical dosage forms.
Picato can be used as use of ingenol mebutate to treat actinic keratosis, topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate.
The generics of Picato are possible to be released after 15 May, 2033.
Drugs and Companies using INGENOL MEBUTATE ingredient
Market Authorisation Date: 23 January, 2012
Treatment: Use of ingenol mebutate to treat actinic keratosis; Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate
Dosage: GEL;TOPICAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic